Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 69 – FOLFIRINEC
2024-515300-39-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in neuroendocrine carcinoma (NEC), apudoma (NET) and gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) comparing mFOLFIRINOX with platinum–etoposide (2 arms). Primary endpoint: Progression-free survival (PFS) by investigator assessment. Planned start Oct 2024; status: authorised.
02
Drugs
FOLFIRINOXcisplatinetoposide
03
Conditions
neuroendocrine carcinoma (NEC)apudoma (NET)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on 2024-515300-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515300-39-00.